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In 11 patients with a recessive congenital disorder, which we refer to as “the hypotonia-cystinuria syndrome,”
microdeletion of part of the SLC3A1 and PREPL genes on chromosome 2p21 was found. Patients present with
generalized hypotonia at birth, nephrolithiasis, growth hormone deﬁciency, minor facial dysmorphism, and failure
to thrive, followed by hyperphagia and rapid weight gain in late childhood. Since loss-of-function mutations in
SLC3A1 are known to cause isolated cystinuria type I, and since the expression of the ﬂanking genes, C2orf34
and PPM1B, was normal, the extended phenotype can be attributed to the deletion of PREPL. PREPL is localized
in the cytosol and shows homology with prolyl endopeptidase and oligopeptidase B. Substitution of the predicted
catalytic residues (Ser470, Asp556, and His601) by alanines resulted in loss of reactivity with a serine hydrolase-
speciﬁc probe. In sharp contrast to prolyl oligopeptidase and oligopeptidase B, which require both aminoterminal
and carboxyterminal sequences for activity, PREPL activity appears to depend only on the carboxyterminal domain.
Taken together, these results suggest that PREPL is a novel oligopeptidase, with unique structural and functional
characteristics, involved in hypotonia-cystinuria syndrome.
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The prolyl oligopeptidase family (SC clan, family S9)
(Rawlings and Barrett 1994) represents a class of serine
peptidases that are selective for small peptides (generally
!30 aa) (Polgar 2002). The four main members are pro-
lyl endopeptidase (PREP) (EC 3.4.21.26; MIM 600400),
oligopeptidase B (OpdB) (EC 3.4.21.83), dipeptidyl-
peptidase IV (DPPIV) (EC 3.4.14.5; MIM 102720), and
acylaminoacyl-peptidase (APEH) (EC 3.4.19.1; MIM
102645) (Polgar 2002). PREP and OpdB are endopep-
tidases that cleave carboxyterminal of proline and ar-
ginine/lysine residues, respectively. DPPIV and APEH,
on the other hand, are exopeptidases. The former is spe-
ciﬁc for proline at the penultimate position, and the lat-
ter removes acylated aminoterminal amino acids from
blocked peptides (Polgar 2002).
The family has a conserved domain structure, with a
b-propeller domain preceding the catalytic domain. The
catalytic triad residues are located in a speciﬁc order (Ser,
Asp, His) and in conserved places (Ollis et al. 1992;
Nardini and Dijkstra 1999). The structural basis for se-
lectivity for small peptides is the b-propeller, which acts
as a gating ﬁlter whose central tunnel excludes large,
structured peptides (Fulop et al. 2000), although this
concept has recently been challenged (Juhasz et al.
2005).
All four enzymes have been implicated in clinical con-
ditions and are potential therapeutic targets. Serum
PREP activity is increased in patients with mania and
schizophrenia (Maes et al. 1995) but decreased in pa-
tients with different stages of depression (Maes et al.
1994). Recent studies indicate that PREP is involved in
the regulation of the inositol (1,4,5)-triphosphate path-
way—the same pathway that is affected by lithium,
which is often used as a therapeutic agent for the treat-
ment of depression (Williams et al. 1999, 2002; Schulz
et al. 2002). OpdB plays a crucial role in the host cell
invasion by the protozoan parasite Trypanosoma cruzi
in Chagas disease, and deletion of the gene results in
greatly reduced cell invasion capacity. OpdB generates
an active Ca2 agonist from a cytosolic precursor mol-
ecule, which results in the recruitment and fusion of host
cell lysosomes at the site of parasite attachment (Burleigh
et al. 1997; Caler et al. 1998, 2000). DPPIV inactivates
glucagon-like peptide-1 and gastric inhibitory polypep-
tide, both of which stimulate insulin release. Inhibiting
DPPIV is a promising strategy in the treatment of dia-
betes type 2 (Drucker 2001; Vilsboll et al. 2001). Finally,
APEH is deleted in a number of small-cell lung carci-
noma cell lines, and it has been suggested that the ac-
cumulation of acetylated peptide growth factors could
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contribute to tumor cell proliferation (Scaloni et al.
1992).
Recently, a 179-kb deletion (2p21 deletion syndrome)
(MIM 606407) containing at least four genes (SLC3A1,
PREPL, PP2Cb, and C2orf34) was found in seven
patients in a small Bedouin clan (Parvari et al. 2001).
One of the genes was found to be homologous to PREP
and was, therefore, named “prolyl oligopeptidase-like”
(PREPL). The contribution of PREPL to the severe syn-
drome, which is characterized by cystinuria type I, hy-
potonia, neonatal seizures, severe mental retardation,
different facial dysmorphism, and mitochondrial dys-
function, could not be established (Parvari et al. 2005).
Here we report a novel syndrome characterized by
hypotonia and cystinuria type I. This hypotonia-cystin-
uria syndrome (HCS) is caused by a microdeletion of
only two genes, SLC3A1 and PREPL. The former en-
codes the heavy-chain subunit of the cystine and dibasic
amino acid transporter localized in the renal proximal
tubule and small intestine (Goodyer et al. 2000). Inac-
tivation of this gene product is known to cause isolated
cystinuria type I (Calonge et al. 1994; Font-Llitjos et al.
2005) (MIM 220100). The other clinical features of the
syndrome can, therefore, be attributed to the gene prod-
uct of PREPL.
Methods
Patients
Patients were studied after informed consent was obtained.
They all presented with hypotonia and feeding difﬁculties from
birth and were referred to us between the ages of 2 wk and 7
mo.
Genomic PCR
The initial semiquantitative PCR analysis of the SLC3A1
locus was performed as described elsewhere (Purroy et al.
2000). For new amplicons, primers were designed using Pri-
mer3 and sequences available in GenBank. PCR products were
ampliﬁed using 150 ng of genomic DNA, by use of either the
PCR Master Mix (Promega) or the Expand Long Template
PCR System (Roche Molecular Biochemicals). Junction frag-
ments were puriﬁed with the Montage PCR Centrifugal Filter
Device (Millipore) before sequencing. All primer sequences and
annealing temperatures are available on request. Primer se-
quences for the microsatellites were obtained from the GDB
Human Genome Database.
Quantitative RT-PCR
RNA from Epstein Barr virus (EBV)–transformed leukocytes
was extracted using the QIAquick RNA extraction kit (Qia-
gen), in accordance with the manufacturer’s protocol. One
microgram of RNA was DNase (Fermentas) treated before
cDNA synthesis with SuperScript II (Invitrogen). cDNA was
diluted four times for analysis. Quantitative PCR was per-
formed using qPCR MasterMix for SYBR Green I detection
(Eurogentec) on the ABI7000 sodium dodocyl sulphate (SDS)
system (Applied Biosystems), in accordance with the manu-
facturer’s guidelines. Primers were developed with Primer-
Express software (Applied Biosystems).
In Silico Analysis
Sequences (EST and homologues) were obtained via BLAST
searches. Multiple sequence alignments were performed using
ClustalW. Subcellular localization was predicted using the
PSORT II program. Secondary structure predictions were per-
formed using PredictProtein and JPRED.
Northern Blotting
A human multiple-tissue northern blot (Clontech Labora-
tories) was hybridized in accordance with the manufacturer’s
protocol. A 1-kb cDNA fragment spanning exons 2–8 was
used as a probe.
Eukaryotic Expression Constructs
Human PREPLS cDNA (GenBank accession number
AB007896) was obtained from the Kazusa DNA Research In-
stitute (Kikuno et al. 2004). Porcine PREP was provided by
L. Polgar (Szeltner et al. 2000). OpdB was PCR ampliﬁed using
DNA from the Escherichia coli K12 strain (GenBank accession
number U00096) as a template. All cDNAs, including those
encoding mutated and truncated proteins, were subcloned into
a pcDNA3.1 expression vector (Invitrogen) introducing an
aminoterminal FLAG epitope tag (DYKDDDDK). All con-
structs and mutations were conﬁrmed by cycle sequencing (Ap-
plied Biosystems).
Site-Directed Mutagenesis
Active site mutants were generated using a QuikChange site-
directed mutagenesis kit (Stratagene), in accordance with the
guidelines of the supplier. Truncated mutants encoding only
the carboxyterminal catalytic domain (PREPL aa 342–638,
OpdB aa 405–687, and PREP aa 426–710) were generated by
PCR and cloned in pcDNA3.1.
Immunopuriﬁcation
HEK293T cells were transiently transfected with the indi-
cated plasmid with the use of Fugene6 (Roche Molecular
Biochemicals). After 24 h of incubation, cells were washed
twice with PBS and were harvested by scraping in ice-cold PBS.
Cells were lysed by 10 passages through a 26-gauge needle.
Cell debris was removed by centrifugation (10,000 g at 4C
for 10 min). FLAG-tagged recombinant protein was immu-
nopuriﬁed from precleared lysate by use of preformed com-
plexes of anti-FLAGM2 antibody (Sigma-Aldrich) and protein
G Sepharose (GE Healthcare), as described elsewhere (Jackson
et al. 2003).
Bacterial Expression and Puriﬁcation
Human PREPLS cDNA was subcloned in the pQE9 expres-
sion vector (Qiagen) with an aminoterminal His epitope. At
30C, 250-ml cultures of E. coli strain M15 (PREP4) were
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Figure 1 Clinical presentation of HCS. A, Patient 5-I during childhood (top) and adulthood (bottom). B, Growth curve of patient 3-I,
illustrating the excellent response to growth hormone treatment. Vertical arrow indicates the age at which the treatment was started.
grown overnight, and expression was induced by the use of
1-mM isopropyl-b-D-thiogalactopyranoside.
Bacterial pellets were resuspended in 100 ml of 50-mM Tris
buffer (pH 8) and were lysed by the addition of 0.1 mg/ml
lysozyme (30 min at 4C), followed by sonication. Cleared
lysates (10 min at 10,000 g) were puriﬁed on the AKTA ex-
plorer (GE Healthcare) with the use of a Ni-NTA afﬁnity col-
umn (Sigma). PREPLS was eluted with imidazole (Merck), at
a concentration of 100 mM. Bacterially produced PREPLS was
used for inhibitor proﬁling.
Reaction with Fluorophosphate-Biotin
Fluorophosphate-biotin (FP-biotin) was synthesized as de-
scribed elsewhere (Liu et al. 1999). Immunopuriﬁed proteins
were resolved in 19.5 ml of a 50-mM phosphate buffer at pH
8. FP-biotin (200 mM in dimethyl sulfoxide) was added to a
ﬁnal concentration of 5 mM, and the reaction mixture was
incubated at 37C for 30 min. Reactions were quenched by
the addition of SDS-PAGE loading buffer (reducing) and heat-
ing at 95C for 10 min.
Competition experiments were performed in a total volume
of 40 ml with the use of 1 mg of bacterially expressed PREPLS
spiked with 250 ng of FLAG M2 for normalization purposes,
as explained below. PREPLS was preincubated in the presence
or absence of inhibitor for 15 min at 37C, followed by a
reaction with FP-biotin for 15 min. Reactions were stopped
by the addition of SDS-PAGE loading buffer (reducing) and
heating at 95C for 10 min.
Detection of FP-Biotin Reactivity
The reactions were run on SDS-PAGE and were transferred
by electroblotting on to a nitrocellulose membrane, as de-
scribed elsewhere (Roebroek et al. 2004). Blots were incubated
with horseradish peroxidase-conjugated streptavidin (Dako),
were visualized by Western Lightning Chemiluminescence Re-
agent Plus (Perkin Elmer Life Sciences), and were exposed with
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Table 1
Neonatal and Relevant Endocrinological Data on the Patients
Patient Sex
Birth
Weight
(g)
Birth
Length
(cm)
Gestational
Period
(wk)a
Delivery
Methodb
Peak GH
(mg/liter)
IGF-1
(SD score)
Age at Puberty
(years)c
FSH
(U/liter)d
1-I M 2,600 44 36 CS (breech) 110 2.3 !9 NAe
2-I M 3,510 50.5 41 Induction NA NA !9 NAe
8-I M 3,970 52 41 NL 6.6 1.8 NA NL
3-I M 3,600 50 40 CS (breech) 7.3 4.8 13.1 NL
7-I M 2,800 49 40 Induction 5 3.7 13.4 16.6f
6-I M 3,500 NA NA NA NA NA NA NA
7-II F 2,890 NA 40 NL 110 2.8 12.5 22.8g
4-I F 3,250 52 40 CS 6 2.6 13.7 52.8
8-II F 2,880 49 41 NL 2 3.1 Primary amenorrea 76
9-I F 3,450 51 41 NL !2 3.7 15 NA
5-I F 1,900 NA NA NA NA NA 15 NL
NOTE.—NL p normal. NA p not available.
a Weeks of pregnancy, counting from mother’s last menstruation.
b CS p cesarean section.
c For males, age at which testes 14 ml. For females, age at menarche.
d FSH normal values !10 U/liter.
e Age !9 years.
f Orchidopexy at age 5 years.
g Premenarcheal, regular menses.
Super RX medical x-ray ﬁlm (Fuji). The expression of recom-
binant protein was subsequently conﬁrmed on the same blot
with the use of biotinylated anti-FLAG M2 antibody.
In the competition experiments, the FLAGM2 antibody was
detected by the incubation of the lower part of the blot with
horseradish peroxidase-conjugated rabbit antimouse antise-
rum (Dako). Chemiluminescence signals of both FP-biotin and
FLAG M2 were quantiﬁed using the Kodak Image Station
440C (Perkin Elmer Life Sciences). The FLAG M2 signal was
used for normalization.
Immunocytochemistry
Chinese hamster ovary (CHO)–K1 cells were transfected as
described elsewhere (Creemers et al. 2000) and were analyzed
24 h later. Immunocytochemistry was performed essentially
as described elsewhere (Creemers et al. 1996), except that the
cells were washed and ﬁxed for 5 min in methanol at 20C.
Slides were analyzed on a Zeiss Axiophot ﬂuorescence micro-
scope equipped with an RT slider SPOT CCD camera (Di-
agnostic Instruments) that used SPOT RT software.
Activity Studies
Substrate speciﬁcity of PREPL was tested using ﬂuorogenic
substrates (peptidyl 4-methyl-7 coumarylamide [Bachem]). Im-
munopuriﬁed proteins were resuspended in 95 ml of reaction
buffer (50-mM phosphate buffer at pH 8, 10-mM EDTA, and
2-mM dithiothreitol) and were preincubated at 37C for 5min.
Substrate was added at a ﬁnal concentration of 200 mM. Fluo-
rogenic leaving groups were detected in real time, by use of a
FLUOstar Galaxy (BMG Labtechnologies) spectroﬂuorimeter,
at excitation and emission wavelengths of 390 nm and 420
nm, respectively.
Results
Hypotonia-Cystinuria Syndrome
Eleven patients (six male and ﬁve female) from nine
families were studied. Seven of the nine families were
Flemish (from Antwerp, Belgium) and two were French
(from Normandy, France). Although the Flemish pa-
tients lived within an area of only 80 km # 20 km,
consanguinity could not be documented between par-
ents. The oldest patient was described with cystinuria,
benign myopathy, and dwarﬁsm (Clara and Lowenthal
1966). His three similarly affected siblings were lost to
follow-up and were, therefore, not included in this study.
The parents and siblings of nine patients underwent
a complete clinical examination and urine amino acid
analysis, but no abnormalities were found. The ages of
the patients ranged from 4 years to 42 years. Decreased
fetal movements were reported in nine patients. Five chil-
dren were born by cesarean section or induction, and
the others had a tendency towards postdatism. Mean
birth weight ( ) was0.77 SD. All patients showednp 9
a generalized hypotonia from birth, with major feeding
problems (mainly anorexia) necessitating gavage feeding
in three patients and a gastrostomy in one. Failure to
thrive persisted up to the ages of 6–8 years, and a period
of hyperphagia and rapid weight gain followed.
All showed minor facial dysmorphism, characterized
mainly by dolichocephaly and ptosis of the eyelids; the
latter improved with age but did not completely dis-
appear (ﬁg. 1A). Tented upper lip was noted in four
patients. Thick and/or decreased saliva was reported in
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Figure 2 Genetics of HCS. A, Deletions present in the HCS families. All deletions disrupt the coding sequences of SLC3A1 and PREPL,
located on chromosome 2p21. Sizes range from 23.8 kb to 75.5 kb. Sequences ﬂanking the breakpoints are shown and are numbered in
accordance with BAC clone 24i5. B, Junction fragments spanning the breakpoint. C, Haplotype analysis for deletion A, B, and C alleles. Dashed
lines indicate the breakpoint. Conserved alleles are shaded in gray. For deletion B, the conserved subhaplotypes proximal to the breakpoint are
shaded in light gray and dark gray. Families 5 (deletion B/deletion B) and 6 (deletion A/deletion B) are excluded because parents were not
available. pp Paternal haplotype; mp maternal haplotype.
six patients. Gross motor development was mildly to
moderately retarded, with unaided walking achieved be-
tween the ages of 15 mo and 3 years. Fine motor de-
velopment was normal. Speech was normal or mildly
retarded, but all patients exhibited nasal speech. Of the
seven patients older than 6 years, four received normal
educations, and the remaining three received special
educations.
Epileptic phenomena were not recorded in any of the
patients. Impaired growth became evident in eight of
nine patients at a median age of 3 years (range 2–6
years), either by decreased growth velocity or by the
absence of growth acceleration while rapid weight gain
occurred. In six of the eight patients, peak growth hor-
mone levels after two different provocation tests were
insufﬁcient. Priming with sex hormone was performed
when necessary. Two patients had repeatedly low levels
of IGF-1. Growth hormone treatment (25 mg/kg/d) was
started in all eight patients at a median age of 10.7 years
(range 1.4–13.6 years), with excellent results. The me-
dian actual height and height velocity SD score before
the start of growth hormone treatment was2.3 (range
4 to0.9) and1.35 (range2.8 to 0.4), respectively.
Median latest height SD score was 0.3 (range 2 to
1.7) and median latest BMI SD score was 1.7 (range
0.5–2.5). A representative growth curve is presented in
ﬁgure 1B.
There was a tendency towards late puberty in seven
of nine patients, four of whom presented hypergona-
dotropic hypogonadism (range of basal serum follicle
stimulating hormone [FSH] 17–76 U/liter) (table 1). Se-
rum dehydroepiandrosterone sulfate levels were low in
all children older than 6 years, a ﬁnding suggestive of
lowered adrenarche. Serum prolactin levels were not
elevated.
All patients presented within their ﬁrst decades with
symptomatic nephrolithiasis due to classical cystinuria
type I. Further metabolic work-upwas normal, including
hemograms and tests of blood lactate, pyruvate, glucose,
plasma amino acids, serum free and total carnitine, acyl-
carnitines, creatine kinase, lactate dehydrogenase, in-
sulin, liver function, sialotransferrins, and urinary or-
ganic acids.
Electromyography and nerve conduction velocity
were normal in all patients. A brain scan or magnetic
resonance imaging was performed in seven patients with
normal results, except in one patient with a small-sized
anterior pituitary gland. Muscle biopsy performed in
three patients (aged 6 mo, 8 mo, and 1 year) did not
show any speciﬁc abnormality. In particular, there was
no histological evidence for mitochondrial disease, and
the enzymatic activity of mitochondrial respiratory chain
complex I–V was normal. An imprinting defect on chro-
mosome 15 was ruled out by methylation analysis with
the use of the KB17 probe (Buiting et al. 1998) (data
not shown), excluding Prader-Willi syndrome (PWS).
Deletion Screening of the SLC3A1 Locus
Isolated cystinuria type I is caused by mutations in
SLC3A1 (Calonge et al. 1994). Two siblings were shown
elsewhere to be compound heterozygous for deletions in
this gene (Purroy et al. 2000). On one allele, exons 2–
10 were deleted, whereas on the other, only exon 10 was
missing. The SLC3A1 gene was therefore screened in the
remaining nine patients by use of semiquantitative PCR
analysis. Deletions were detected in all patients. The
presence of the deleted allele was conﬁrmed in the par-
ents, if available. The region proximal to the SLC3A1
gene was subsequently analyzed to estimate the size of
the deletions.
Primers ﬂanking the breakpoint were used to generate
junction fragments (ﬁg. 2B and table A1 [online only]).
Subsequently, these junction fragments were sequenced
to determine the exact breakpoints. In total, four unique
deletions were found (ﬁg. 2A). Their sizes range from
23.8 kb to 75.5 kb. The distribution of the different
alleles is presented in table 2. The different deletions
disrupt the coding regions of only two genes, SLC3A1
and PREPL (KIAA0436 and FLJ16627).
To exclude the possibility that the deletions also affect
the two ﬂanking genes—C2orf34 (FLJ23451), located
proximal to PREPL, and PPM1B, located distal to
SLC3A1—we have analyzed their expression in the EBV-
transformed leukocytes of one patient with deletion B.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression was used to normalize the data. As is shown
in table 3, similar expression levels were observed in
patient and controls.
Haplotype Analysis
Only four different deletions were found on a total of
18 independent chromosomes. Deletions A, B, C, and
D are represented 4, 11, 2, and 1 times, respectively. We
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Table 2
Genotypes Present in HCS Families
Family
Maternal
Deletion
Paternal
Deletion Sib Pair Origin Reference
1 A A No Belgium …
2–5 B B No Belgium …
6 A/Ba A/Ba No Belgium Clara and Lowenthal 1966
7 B A Yes Belgium Purroy et al. 2000
8 C C Yes France …
9 D B No France …
a Phase unknown.
Table 3
Expression Analysis of C2orf34 by Use of Quantitative PCR
Cycle
Threshold
Control 1
(Ct)
Control 2
(Ct)
Control 3
(Ct)
Patient 4-I
(Ct)
Blank
(Ct)
C2orf34 28.65 28.18 28.59 28.59 39.25
PPM1B 27.15 26.91 27.56 27.65 39.54
GAPDH 19.00 19.07 19.30 19.52 35.35
examined, using microsatellites and SNPs, whether the
ﬁrst three deletions arose from common ancestors. Five
microsatellites (D2S119, D2S2298D2S2174,D2S2280,
and D2S2291) and 10 SNPs were genotyped. Alleles in
linkage disequilibrium were combined into one data
point (table A2 [online only]). Conserved haplotypes for
markers ﬂanking the breakpoint were found in alleles
of deletion A and C. The haplotypes for deletion B can
be subdivided into two groups, with a conserved hap-
lotype distal to the breakpoint. Informative haplotypes
are shown in ﬁgure 2C.
In Silico Analysis of PREPL
Analysis of the 5′ UTR by use of EST data from the
public databases revealed a complex splicing pattern (ﬁg.
3B). Evidence for at least seven splice variants was found
with the use of two alternative transcription start sites
and two additional exons between the predicted exon 1
and 2 (Parvari et al. 2001), which we have named exons
1A and 1B (ﬁg. 3A and 3B). PREPL3 and PREPL5 use
the ﬁrst transcriptional start, whereas the other isoforms
all start 259 bp later. The most prevalent isoforms,
PREPL1–4, splice from exon 1 (at different positions) to
exon 2, which harbors the translational start with an
inframe stop codon 28 codons upstream of the initiator
methionine. This generates the 638-aa short form of the
protein (ﬁg. 3A and 3B and ﬁg. 4B), which we refer to
as PREPLS. On the other hand, splice variants PREPL5–
7 do not directly splice to exon 2. An inframe start codon
is present in exon 1B, which results in a protein with
an additional 89 aa and is referred to as PREPLL (ﬁg.
3A and 3B and ﬁg. 4B). A multiple sequence alignment
and clone numbers for the different isoforms can be
found in ﬁgure A1 (online only) and appendix B (online
only).
The 3′ UTR contains at least three polyadenylation
signals, which all appear to be used on the basis of north-
ern blot analysis and EST clones. Three groups of EST
clones were found with a 3′ UTR of 2,591 bp, 1,703
bp, and 520 bp (appendix C [online only]). This results
in a ubiquitously expressed ∼5.1-kb mRNA and tissue-
restricted ∼4.1-kb (brain) and ∼2.8-kb (kidney) tran-
scripts (ﬁg. 3C). Northern blot analysis further revealed
a broad tissue distribution of PREPL, with the highest
expression in brain, heart, kidney, and skeletal muscle.
Protein Homology and Secondary Structure Prediction
Orthologues of PREPL are found in all vertebrates,
with identities ranging from 40% (Tetraodon nigrovir-
idis) to 94% (Mus musculus and Rattus norvegicus) to
99% (Pan troglodytes) (calculated for the PREPLS [ﬁg.
4A]). Orthologous genes are located within syntenic
regions of the different species.
BLAST searches revealed homology with PREP and
OpdB, with an overall similarity of 29% and 44%, re-
spectively (ﬁg. 4A and 4B). The crystal structure of PREP
has been determined and shows two distinct domains,
a b-propeller and a catalytic domain. The catalytic do-
main, which is composed of the aminoterminal 72 aa
and the carboxyterminal 283 aa, shows a typical a/b–
hydrolase fold (Ollis et al. 1992), and the b-propeller
domain is composed of b-sheets (Fulop et al. 1998).
PREPLS seems to be lacking the aminoterminal com-
ponent of the catalytic domain. The PREPLL variant is
longer at the amino terminus, but sequence homology
with PREP and OpdB is low. However, secondary struc-
ture predictions show similar fold components (ﬁg. 5).
Furthermore, in both variants, the last 68 aa of the car-
boxyterminus share no signiﬁcant sequence homology,
although secondary structure predictions suggest that
the a/b–hydrolase fold remains intact (ﬁg. 4B and ﬁg.
5). Moreover, the putative catalytic residues (Ser470 and
Asp556) are conserved at the topologically equivalent
positions, whereas the catalytic histidine is located in the
nonconserved carboxyterminus, most likely His601 or
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Figure 3 Expression analysis of PREPL. A,Genomic organization of PREPL. B, In silico analysis of the 5′ UTR revealed two transcriptional
start sites. The ﬁrst transcription start is present in isoforms PREPL3 and PREPL5, and the second is present in the remaining isoforms. Isoforms
PREPL1–4 use the start codon in exon 2, generating a 638-aa protein. PREPL5–7 isoforms contain an additional start site in exon 1B, generating
a 727-aa protein. C, Human multiple-tissue northern blot shows a broad tissue distribution of a 5.1-kb transcript, with highest expression in
brain, kidney, and skeletal muscle. Tissue speciﬁc transcripts are present in brain (∼4.1 kb) and kidney (∼2.8 kb) tissue.
His607. The b-propeller shows relatively low sequence
identity. Nevertheless, secondary structure predictions
indicate the presence of b-sheets only, which is charac-
teristic for a b-propeller fold (ﬁg. 5).
Structural analysis of PREP and OpdB indicate that
the S1 binding pocket is formed by a number of amino
acids. In PREP, Trp595 plays a crucial role in aligning
the proline (Fulop et al. 1998). In OpdB, on the other
hand, Glu576 and Glu578 form a negatively charged
pocket, accommodating a basic residue (Gerczei et al.
2000). Multiple alignments with PREP, OpdB, and
PREPL show that the equivalent positions in PREPLS
(Glu514 and Glu516) also form a negatively charged
pocket, so a basic residue (Arg or Lys) at the P1 position
of the substrate (i.e., the ﬁrst residue aminoterminal of
the cleavage site) (Berger and Schechter 1970) is ex-
pected (ﬁg. 5).
Cellular Localization
The prediction for subcellular localization by use of
the PSORT II program is cytosolic (probability 70%)
and nuclear (probability 22%) for the PREPLS isoform.
This is the same localization as that for its family mem-
bers PREP and OpdB. However, the PREPLL isoform lo-
cation is predicted to be cytoplasmic (probability 39%),
nuclear (probability 26%), or mitochondrial (probabil-
ity 17%). Immunocytochemistry in CHO cells shows
cytoplasmic staining for both isoforms. No evidence was
found of a nuclear or mitochondrial distribution for the
PREPLL variant (ﬁg. 6A).
Substrate Speciﬁcity
Substrate speciﬁcity of PREPL was tested using sub-
strates typical for PREP (Yoshimoto et al. 1979) and
OpdB (Morty et al. 2002). Although all substrates were
efﬁciently cleaved by the corresponding oligopeptidase,
no cleavage by PREPL was observed (data not shown).
Furthermore, we examined the possibility that PREPL
is an aminopeptidase or aminodipeptidylpeptidase with
a proline or arginine preference (data not shown). Again,
no activity was detected.
Activity Proﬁling
Experimental evidence for serine hydrolase activity
was provided using FP-biotin (Liu et al. 1999), a bio-
tinylated derivative from the serine hydrolase inhibitor
diisopropylﬂuorophosphate (DFP). FP-biotin binds co-
valently to the active site serine only if it resides in a
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Figure 4 The PREPL homologues. A, Amino acid identity of different PREPLS orthologues and amino acid similarity of different PREPLS
homologues. The light-gray and dark-gray bars represent the identity (left panel) or similarity (right panel) percentages of the complete sequence
and catalytic domain, respectively. An asterisk indicates an incomplete amino acid sequence present in the database. B, Schematic representation
of the domain structure of the PREPL isoforms. Identity/similarity percentages of the different domains with PREP and OpdB are shown.
catalytically active conformation. As shown in ﬁgure 6B,
FP-biotin reacts with epitope-tagged recombinant
PREPLS and PREPLL but not with PREPLS mutants in
which a putative catalytic triad residue has been replaced
by an alanine residue (ﬁg. 6C). The reaction of mutant
His607Ala was similar to wild type, whereas the mu-
tation of His601 completely abolished reactivity, iden-
tifying His601 as a genuine catalytic residue.
Since all components of the a/b–hydrolase fold are
present in the carboxyterminal part of the catalytic
domain, we used the activity-based probe to test the
folding of this domain in the absence of the propeller
domain and aminoterminal component of the catalytic
domain. Wild-type PREPLS, PREP, and OpdB react with
FP-biotin, whereas only the isolated catalytic domain of
PREPL reacts with FP-biotin (ﬁg. 6D).
FP-biotin can also be used to proﬁle the potency of
inhibitors in a complex mixture of enzymes (Leung et
al. 2003). Using this technique, we have generated an
inhibitor proﬁle for PREPLS. Typical serine protease in-
hibitors like PMSF and Prefabloc inhibit PREPL com-
pletely, as does leupeptin at high concentrations. TPCK,
a chymotrypsin inhibitor, and E64, a cysteine protease
inhibitor, partially inhibit FP-biotin reactivity. No effect
was seen with 4-amidinophenyl-methanesulfonyl ﬂour-
ide (APMSF), pepstatin, or EDTA (table 4).
Discussion
HCS is an autosomal recessive trait characterizedmainly
by hypotonia, cystinuria, minor facial dysmorphism, and
growth hormone deﬁciency. Molecular analysis has re-
vealed deletions in all patients. In total, four different
deletions were identiﬁed, ranging from 23.8 kb to 75.8
kb. The smallest region of overlap is 7.7 kb. The coding
sequences of two genes, SLC3A1 and PREPL, are dis-
rupted. Although the deletion of regulatory elements of
neighboring genes cannot be entirely excluded, expres-
sion studies of the ﬂanking genes, C2orf34 and PPM1B,
in an EBV-transformed lymphocyte cell line of one pa-
tient with the largest deletion showed the same expres-
sion as controls. Comparison with the homozygous
2p21 deletion syndrome (Parvari et al. 2001) shows sim-
ilar features, such as cystinuria, growth impairment, and
hypotonia, although the latter appears to be less severe
in HCS. On the other hand, neonatal seizures, severe
mental retardation, distinct dysmorphic features, and
mitochondrial dysfuntion are unique to the 2p21 dele-
tion syndrome and are most likely caused by the absence
of the additional genes.
The nine unrelated families live in two small geo-
graphic regions. Since only four different deletions were
detected, founder effects for deletions A, B, and C were
examined using haplotype analysis. Conserved haplo-
types ﬂanking the breakpoint were detected in deletions
A and C, which extended over at least 1 Mb and 2 Mb,
respectively. In patients with deletion B, the conserved
haplotype distal to the breakpoint extended over at least
0.7 Mb. Proximal to the breakpoint, two distinct hap-
lotypes are present, most likely because of a crossing-
over event shortly after the deletion ﬁrst appeared. In
conclusion, these data support the hypothesis that each
of these deletions (A, B, or C) has occurred only once.
Their respective ancestral haplotypes are thus still pre-
sent in our patient group.
The prevalence of microdeletions in this genomic re-
gion is hard to estimate. Our observation of two differ-
ent alleles in a small region of Belgium (Antwerp) and
three different deletions in Normandy, France (one of
which is also found in Belgian patients), suggests the
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Figure 6 Functional analysis of PREPL. A, Immunoﬂuorescence analysis of PREPLS and PREPLL in CHO cells. Both isoforms show similar
cytoplasmic staining, and similar results were obtained for PREPLS when the FLAG epitope was linked to the carboxyterminus instead of to
the aminoterminus. B, Enzymatic activity of immunopuriﬁed, recombinant proteins was determined using FP-biotin and was visualized with
streptavidin-HRP. Expression of recombinant proteins was conﬁrmed with biotinylated anti-FLAG M2 antibody. C, Wild-type PREPLS (lane 2)
and mutant His607Ala (lane 6) show reactivity with FP-biotin. In contrast, mutations of the predicted catalytic residues (lanes 3, 4, and 5)
ablated activity. D, Full-length PREPLA–B, OpdB, and PREP are all FP-biotin reactive. Reactivity was abolished in the truncated constructs of
OpdB and PREP (lanes 4 and 6) but not in truncated PREPL (lane 2), conﬁrming the fundamental difference in domain structure. DPREPLp
truncated construct of PREPL (aa 342–638), DOpdBp truncated construct of OpdB (aa 405–687), and DPREPp truncated construct of PREP
(aa 428–710).
prevalence might be relatively high. In addition, three
patients who have cystinuria type I with one mutated
allele and one deletion of SLC3A1, including the 3′ UTR
(which overlaps with exon 14 of PREPL), have been
reported but not characterized (Bisceglia et al. 1996;
Saadi et al. 1998; Font-Llitjos et al. 2005). A phe-
notype besides cystinuria type I is not expected, since
only one PREPL allele is deleted. Furthermore, one spo-
radic case with similar phenotype has been reported else-
where (Zaffanello et al. 2003). Molecular diagnosis of
the SLC3A1/PREPL locus was suggested but was not
performed. It should also be noted that microdeletion
of only PREPL would result in a phenotype that is much
less distinct in the absence of cystinuria and that will,
therefore, be more difﬁcult to recognize.
Although the syndrome displays some clinical char-
acteristics (neonatal hypotonia, childhood-onset obesity,
short stature, viscous saliva, and hypogenitalism) similar
to those seen in PWS, there are striking differences. The
neonatal hypotonia described in infants with PWS is
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Table 4
Inhibitor Proﬁle Based on FP-Biotin
Reactivity
Inhibitora
Reactivity
(%)
SD
(%)
5-mM PMSF 0 0
1-mM PMSF 14 10
250-mM E64 23 6
25-mM E64 89 15
1.25-mM TPCK 30 9
250-mM TPCK 60 5
6.25-mM Prefabloc 0 0
1.25-mM Prefabloc 10 2
125-mM APMSF 55 7
12.5-mM APMSF 101 14
1.25-mM Leupeptin 4 2
250-mM Leupeptin 79 11
12.5-mM EDTA 125 5
12.5-mM Pepstatin 75 11
a Inhibitors were preincubated with
PREPLS for 15min before reactionwith FP-
biotin.
more severe, with extreme feeding difﬁculties and the
absence of crying. Children with HCS have mild-to-
moderate obesity, which is different from the insatiable
appetite leading to morbid obesity seen in persons with
PWS. Facial dysmorphism is minor in HCS, and the
growth of hands and feet is normal. The severe behav-
ioral problems starting during childhood in patientswith
PWS have not been observed in children with HCS. Hy-
pogenitalism is noticed in both syndromes, but, unlike
adolescents with PWS, most adolescents with HCS ex-
perience a normal pubertal development. In addition,
typical PWS symptoms, such as sleeping difﬁculties, a
high threshold for pain or vomiting, and a disturbed
thermoregulation, are not observed in persons with
HCS.
Since it is well established that mutations in SLC3A1
cause isolated cystinuria type I, we have focused on char-
acterizing the PREPL gene. While this article was in
preparation, a study describing the expression and com-
plex splicing of PREPL, with similar results, was pub-
lished (Parvari et al. 2005). PREPL is ubiquitously ex-
pressed, albeit with much higher expression, in the brain,
skeletal muscle, heart, and kidney. Involvement of the
brain and skeletal muscle tissues are consistent with the
mild mental retardation and hypotonia, whereas no ab-
normalities (other than cystinuria type I) are observed
in heart and kidney tissue. Two groups of transcripts
were distinguished: the PREPL1–4 and PREPL5–7 iso-
forms, which encode 638-aa and 727-aa proteins, re-
spectively. The former group represents the majority of
the EST clones and is ubiquitously expressed, whereas
the latter is more tissue speciﬁc.
PREPLL contains 103 aa preceding the b-propeller do-
main, which shares no signiﬁcant sequence homology
with its counterpart in PREP and OpdB. On the other
hand, a similar secondary structure is predicted. Unlike
PREP and OpdB, however, this subdomain is redundant
for FP-biotin reactivity. PREPL also does not appear to
contain a sorting signal, since both isoforms are localized
in the cytosol. PREPL shares no signiﬁcant homology
with OpdB and PREP in the last 68 aa of the carbox-
yterminus, although secondary structure predictions
suggest that the a/b–hydrolase fold remains intact. Since
the crystal structure of PREP demonstrates that those
amino- and carboxytermini are in close proximity and
are connected through many hydrogen bonds, salt
bridges, and hydrophobic interactions, it appears that
this subdomain is replaced by a unique subdomain in
PREPL, composed only of the carboxyterminal 68 aa.
This is consistent with the observation that the most
abundant form, PREPLS, lacks the aminoterminal sub-
domain entirely.
The activity of endogenous PREPL (most likely
PREPLS) in mouse brain by use of FP-biotin was reported
elsewhere (Liu et al. 1999). Since no substrates of PREPL
have been identiﬁed so far, we have used this activity-
based probe to identify the catalytic site residues Ser470,
Asp554, and His601 and to generate an inhibitor proﬁle.
This inhibitor proﬁle strongly suggests that PREPL is a
serine protease.
Residues forming the S1 substrate pocket (PREPLS
E514 and E516) are conserved between PREPL and
OpdB, suggesting substrate selectivity for basic residues.
Moreover, leupeptin, a peptide-based inhibitor with a
P1 arginal goup, inhibits the FP-biotin reaction.We have
tested this hypothesis with the use of ﬂuorescent sub-
strates and small peptides, but no activity was detected.
A prolyl peptidase activity was also ruled out with the
use of typical ﬂuorescent PREP substrates. An unbiased
approach using degenerate peptide libraries (Turk et al.
2001; Turk and Cantley 2004) did not reveal speciﬁc
activity (data not shown). This raises the possibility that
PREPL has more-stringent substrate requirements than
PREP and OpdB, which select almost exclusively on the
basis of the P1 amino acid. Determination of the sub-
strate speciﬁcity of PREPL will help unveil the molecular
mechanism underlying the pathophysiology of HCS.
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